Overcoming Resistance In Cancer

ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs. Relapsed patients lack further treatment options. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.

ORIC was founded by two world-class experts in oncology, Charles Sawyers and Scott Lowe, who have strong records of discovering innovative treatments and targets in cancer. Dr. Sawyers was instrumental in the discovery and development of Gleevec, a treatment for chronic myelogenous leukemia, and enzalutamide and ARN-509, both for the treatment of castration-resistant prostate cancer. Dr. Lowe identified BRD4 as a therapeutic target in acute myeloid leukemia and drugs directed against this target are currently in clinical trials. ORIC has assembled a team of highly-experienced scientists who are executing multiple drug discovery strategies targeting the mechanisms that allow tumors to become resistant to current therapies. In addition, the scientific team has unparalleled access to the operational expertise of advisors who have devoted their careers to oncology drug development. Finally, the Company is supported by investors with extensive experience in both drug development and the financing of life science companies.